A 32-year-old woman from Mumbai presents with 14 days of fever, myalgia, and diarrhea. Blood and stool cultures both grow Salmonella typhi. She is allergic to beta-lactams (documented anaphylaxis to penicillin). Her temperature is 39.2°C, and she is alert and oriented. Susceptibility testing shows the isolate is susceptible to fluoroquinolones and chloramphenicol but resistant to trimethoprim-sulfamethoxazole. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has culture-confirmed enteric fever with beta-lactam allergy (anaphylaxis) and a susceptible organism. The choice of antibiotic must account for allergy status, organism susceptibility, and drug efficacy. ## Allergy Assessment **Key Point:** **Beta-lactam anaphylaxis is a true IgE-mediated allergy and is a contraindication to cephalosporins.** Cross-reactivity between penicillins and cephalosporins is ~1–3% in true IgE-mediated reactions. Desensitization is NOT indicated for uncomplicated enteric fever when effective alternatives exist. ## Antibiotic Options in Beta-Lactam Allergy | Agent | Efficacy | Notes | Recommendation | |-------|----------|-------|----------------| | **Fluoroquinolone (Ciprofloxacin)** | Excellent | Excellent intracellular penetration, oral bioavailability, no cross-reactivity | **First choice** | | **Chloramphenicol** | Good | Older agent, bone marrow suppression risk, requires monitoring | Alternative if FQ contraindicated | | **Azithromycin** | Poor | Inadequate for enteric fever, not standard therapy | Not recommended | | **Cephalosporin** | Excellent | Cross-reactivity risk with penicillin anaphylaxis; desensitization not justified | Avoid | ## High-Yield: **In beta-lactam-allergic patients with enteric fever, fluoroquinolones (ciprofloxacin 500 mg IV/PO 12-hourly) are the preferred first-line alternative.** They have: - Excellent intracellular penetration (reach macrophages and bile) - Oral bioavailability (can switch from IV to PO) - No cross-reactivity with beta-lactams - Proven efficacy in enteric fever ## Clinical Pearl: **Chloramphenicol was the historical first-line agent before fluoroquinolones became available.** While effective, it carries a risk of dose-dependent and idiosyncratic bone marrow suppression and requires baseline and periodic CBC monitoring. Fluoroquinolones have largely replaced it due to superior safety and convenience. ## Why NOT Desensitization? 1. Desensitization is reserved for life-threatening infections where no alternatives exist 2. Effective alternatives (fluoroquinolones) are available 3. Uncomplicated enteric fever does not justify the risk of desensitization protocol